glp 1 analogues diabetes GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1-based therapies for type 2

Our in-depth guide decodes the complexities surrounding pricing strategies, negotiations, and the impact of PBMs on healthcare costs

MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, eme

Explore the latest research on GLP-1 medications, kidney health, and the vital role of hydration in preventing stones during weight loss.

Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.

Tresiba (insulin degludec) is used to treat diabetes mellitus

Composite kidney events were reported in 134 (38.2%) and 393 (44.2%) patients in the GLP-1RA and DPP-4i groups, respectively (subdistribution HR 0.72, 95% CI 0.560.93)